The health impact of delaying direct‐acting antiviral treatment for chronic hepatitis C: A decision‐analytic approach

Abstract

BACKGROUND & AIMS: Direct-acting antivirals (DAAs) are highly effective, but expensive treatments for chronic hepatitis C (CHC). To manage costs, drug plans worldwide have rationed access to DAAs in a variety of ways. This study quantifies the health impact of formulary restrictions and presents a clinical decision tool for informing treatment timing decisions. METHODS: A decision-analytic model was developed to quantify the health impact of …

Authors

Erman A; Wong WWL; Feld JJ; Grootendorst P; Krahn MD

Journal

Liver International, Vol. 40, No. 1, pp. 51–59

Publisher

Wiley

Publication Date

1 2020

DOI

10.1111/liv.14247

ISSN

0106-9543

Associated Experts

Paul Grootendorst

Adjunct Associate Professor, Faculty of Social Sciences

Visit profile

Labels